Profound gastric mucosal changes and severe rebound acid hypersecretion after long-term Vonoprazan use: A case report
- PMID: 39712905
- PMCID: PMC11662994
- DOI: 10.1002/deo2.70046
Profound gastric mucosal changes and severe rebound acid hypersecretion after long-term Vonoprazan use: A case report
Abstract
Vonoprazan is a novel acid blocker with greater potency than proton pump inhibitors. A Japanese study reported no significant safety concerns over 5 years of Vonoprazan use; however, elevated serum gastrin and increased parietal cell and foveolar hyperplasia were observed, and long-term safety data beyond 5 years are limited. We report a case that used Vonoprazan for 6 years, complicated by significant gastric epithelial changes during treatment and acute duodenal mucosal lesions following its discontinuation. A 76-year-old, treated with proton pump inhibitors for over 10 years, was switched to Vonoprazan due to his worsening symptoms. After its use, hemorrhagic hyperplastic polyps became prominent. Given concerns about Vonoprazan's effect on the gastric epithelium, the medication was changed to high-dose H2 blocker therapy. Two months later, the patient complained of vomiting and black tarry stools. Esophagogastroduodenoscopy revealed a significant reduction of gastric polyps but multiple erosions and ulcers in the duodenum. This case indicates the potent effects of Vonoprazan on the gastric mucosa and the risk of severe rebound acid hypersecretion after its long-term use.
Keywords: Vonoprazan; gastric mucosa; gastroesophageal reflux; proton pump inhibitors; rebound acid hypersecretion.
© 2024 The Author(s). DEN Open published by John Wiley & Sons Australia, Ltd on behalf of Japan Gastroenterological Endoscopy Society.
Conflict of interest statement
None
Figures




Similar articles
-
Use of vonoprazan, a novel potassium-competitive acid blocker, for the treatment of proton pump inhibitor-refractory reflux esophagitis in patients with systemic sclerosis.J Scleroderma Relat Disord. 2022 Feb;7(1):57-61. doi: 10.1177/23971983211021747. Epub 2021 Jun 7. J Scleroderma Relat Disord. 2022. PMID: 35386943 Free PMC article.
-
Long-term changes in serum gastrin levels during standard dose vonoprazan therapy.Scand J Gastroenterol. 2022 Dec;57(12):1412-1416. doi: 10.1080/00365521.2022.2097893. Epub 2022 Jul 13. Scand J Gastroenterol. 2022. PMID: 35830502
-
Endoscopic findings and outcomes of gastric mucosal changes relating to potassium-competitive acid blocker and proton pump inhibitor therapy.DEN Open. 2024 Jun 24;5(1):e400. doi: 10.1002/deo2.400. eCollection 2025 Apr. DEN Open. 2024. PMID: 38919514 Free PMC article. Review.
-
Vonoprazan-associated Gastric Mucosal Redness: A Report of Four Cases.Intern Med. 2020 Feb 15;59(4):507-511. doi: 10.2169/internalmedicine.3715-19. Epub 2019 Oct 15. Intern Med. 2020. PMID: 31611534 Free PMC article.
-
Clinical Implications of Proton Pump Inhibitors and Vonoprazan Micro/Nano Drug Delivery Systems for Gastric Acid-Related Disorders and Imaging.Nanotheranostics. 2024 Sep 30;8(4):535-560. doi: 10.7150/ntno.100727. eCollection 2024. Nanotheranostics. 2024. PMID: 39507107 Free PMC article. Review.
References
-
- Ochiai Y, Ito S, Kikuchi D, Hoteya S. Long‐term endoscopic change of gastric polyp associated with administration of vonoprazan. Clin J Gastroenterol 2024; 17: 598–601. - PubMed
-
- Hongo M, Fujimoto K. Incidence and risk factor of fundic gland polyp and hyperplastic polyp in long‐term proton pump inhibitor therapy: A prospective study in Japan. J Gastroenterol 2010; 45: 618–624. - PubMed
-
- Magami Y, Azuma T, Inokuchi H, Moriyasu F, Kawai K, Hattori T. Cell kinetics of slow renewing cell populations in mice stomach. J Gastroenterol Hepatol 2002; 17: 262–269. - PubMed
LinkOut - more resources
Full Text Sources